Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O'Connor T, Velasco MR Jr, Weckstein D, O'Mara A, Loprinzi CL, Shapiro CL. Himelstein AL, et al. JAMA. 2017 Jan 3;317(1):48-58. doi: 10.1001/jama.2016.19425. JAMA. 2017. PMID: 28030702 Free PMC article. Clinical Trial.
Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
Shapiro CL, Moriarty JP, Dusetzina S, Himelstein AL, Foster JC, Grubbs SS, Novotny PJ, Borah BJ. Shapiro CL, et al. Among authors: himelstein al. J Clin Oncol. 2017 Dec 10;35(35):3949-3955. doi: 10.1200/JCO.2017.73.7437. Epub 2017 Oct 12. J Clin Oncol. 2017. PMID: 29023215 Free PMC article. Clinical Trial.
Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.
Basch E, Dueck AC, Rogak LJ, Minasian LM, Kelly WK, O'Mara AM, Denicoff AM, Seisler D, Atherton PJ, Paskett E, Carey L, Dickler M, Heist RS, Himelstein A, Rugo HS, Sikov WM, Socinski MA, Venook AP, Weckstein DJ, Lake DE, Biggs DD, Freedman RA, Kuzma C, Kirshner JJ, Schrag D. Basch E, et al. JAMA Oncol. 2017 Aug 1;3(8):1043-1050. doi: 10.1001/jamaoncol.2016.6749. JAMA Oncol. 2017. PMID: 28208174 Free PMC article. Clinical Trial.
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.
Rosenberg JE, Halabi S, Sanford BL, Himelstein AL, Atkins JN, Hohl RJ, Millard F, Bajorin DF, Small EJ; Cancer and Leukemia Group B. Rosenberg JE, et al. Among authors: himelstein al. Ann Oncol. 2008 May;19(5):946-50. doi: 10.1093/annonc/mdm600. Epub 2008 Feb 13. Ann Oncol. 2008. PMID: 18272914 Free PMC article. Clinical Trial.
The BCSC-1 locus at chromosome 11q23-q24 is a candidate tumor suppressor gene.
Martin ES, Cesari R, Pentimalli F, Yoder K, Fishel R, Himelstein AL, Martin SE, Godwin AK, Negrini M, Croce CM. Martin ES, et al. Among authors: himelstein al. Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11517-22. doi: 10.1073/pnas.1934602100. Epub 2003 Sep 22. Proc Natl Acad Sci U S A. 2003. PMID: 14504409 Free PMC article.
Arterial intimal embrittlement. A possible factor in atherogenesis.
Johnson WT, Salanga G, Lee W, Marshall GA, Himelstein AL, Wall SJ, Horwitz O. Johnson WT, et al. Among authors: himelstein al. Atherosclerosis. 1986 Feb;59(2):161-71. doi: 10.1016/0021-9150(86)90045-6. Atherosclerosis. 1986. PMID: 3964342
11 results